These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16040852)

  • 41. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients.
    Mutsaers HA; Engelke UF; Wilmer MJ; Wetzels JF; Wevers RA; van den Heuvel LP; Hoenderop JG; Masereeuw R
    PLoS One; 2013; 8(8):e71199. PubMed ID: 23936492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins?
    Liabeuf S; Glorieux G; Lenglet A; Diouf M; Schepers E; Desjardins L; Choukroun G; Vanholder R; Massy ZA;
    PLoS One; 2013; 8(6):e67168. PubMed ID: 23826225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modulation of protein fermentation does not affect fecal water toxicity: a randomized cross-over study in healthy subjects.
    Windey K; De Preter V; Louat T; Schuit F; Herman J; Vansant G; Verbeke K
    PLoS One; 2012; 7(12):e52387. PubMed ID: 23285019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An update on uremic toxins.
    Neirynck N; Vanholder R; Schepers E; Eloot S; Pletinck A; Glorieux G
    Int Urol Nephrol; 2013 Feb; 45(1):139-50. PubMed ID: 22893494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Normal and pathologic concentrations of uremic toxins.
    Duranton F; Cohen G; De Smet R; Rodriguez M; Jankowski J; Vanholder R; Argiles A;
    J Am Soc Nephrol; 2012 Jul; 23(7):1258-70. PubMed ID: 22626821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colonic contribution to uremic solutes.
    Aronov PA; Luo FJ; Plummer NS; Quan Z; Holmes S; Hostetter TH; Meyer TW
    J Am Soc Nephrol; 2011 Sep; 22(9):1769-76. PubMed ID: 21784895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy.
    Chiu CA; Lu LF; Yu TH; Hung WC; Chung FM; Tsai IT; Yang CY; Hsu CC; Lu YC; Wang CP; Lee YJ
    Rev Diabet Stud; 2010; 7(4):275-84. PubMed ID: 21713315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease.
    Lin CJ; Chen HH; Pan CF; Chuang CK; Wang TJ; Sun FJ; Wu CJ
    J Clin Lab Anal; 2011; 25(3):191-7. PubMed ID: 21567467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease.
    Wu IW; Hsu KH; Lee CC; Sun CY; Hsu HJ; Tsai CJ; Tzen CY; Wang YC; Lin CY; Wu MS
    Nephrol Dial Transplant; 2011 Mar; 26(3):938-47. PubMed ID: 20884620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.
    Meijers BK; Claes K; Bammens B; de Loor H; Viaene L; Verbeke K; Kuypers D; Vanrenterghem Y; Evenepoel P
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1182-9. PubMed ID: 20430946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients.
    Meijers BK; De Loor H; Bammens B; Verbeke K; Vanrenterghem Y; Evenepoel P
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1932-8. PubMed ID: 19833905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.
    Clayton TA; Baker D; Lindon JC; Everett JR; Nicholson JK
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14728-33. PubMed ID: 19667173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What is new in uremic toxicity?
    Vanholder R; Van Laecke S; Glorieux G
    Pediatr Nephrol; 2008 Aug; 23(8):1211-21. PubMed ID: 18324423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis.
    Pham NM; Recht NS; Hostetter TH; Meyer TW
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):85-90. PubMed ID: 18045861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum.
    de Loor H; Bammens B; Evenepoel P; De Preter V; Verbeke K
    Clin Chem; 2005 Aug; 51(8):1535-8. PubMed ID: 16040852
    [No Abstract]   [Full Text] [Related]  

  • 56. Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD.
    Poesen R; Evenepoel P; de Loor H; Kuypers D; Augustijns P; Meijers B
    Clin J Am Soc Nephrol; 2016 Jul; 11(7):1136-1144. PubMed ID: 27084876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of a sustained difference in hemodialytic clearance on the plasma levels of p-cresol sulfate and indoxyl sulfate.
    Camacho O; Rosales MC; Shafi T; Fullman J; Plummer NS; Meyer TW; Sirich TL
    Nephrol Dial Transplant; 2016 Aug; 31(8):1335-41. PubMed ID: 27190347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption.
    Meijers BK; Weber V; Bammens B; Dehaen W; Verbeke K; Falkenhagen D; Evenepoel P
    Artif Organs; 2008 Mar; 32(3):214-9. PubMed ID: 18201285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New insights into uremic toxicity.
    Raff AC; Meyer TW; Hostetter TH
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):560-5. PubMed ID: 18941347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Uremic solutes from colon microbes.
    Meyer TW; Hostetter TH
    Kidney Int; 2012 May; 81(10):949-954. PubMed ID: 22318422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.